Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-04-18 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗关于2023年年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the proposed cash dividend per share, the total dividend amount, and the approval process including board and supervisory committee meetings. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. It is not a full annual report or interim report, nor is it a simple notification of report publication. The content aligns with a Notice of Dividend Amount (DIV) filing, as it announces dividend amounts, payment basis, and conditions for shareholder approval.
2024-04-18 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2023年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guojin Securities Co., Ltd. regarding the 2023 annual verification opinion on the deposit and use of raised funds by Wuxi Xiangsheng Medical Technology Co., Ltd. It includes extensive financial data on the amount of funds raised, their storage, usage, investment projects, cash management, and compliance with regulatory requirements. The document references specific regulatory frameworks and includes detailed tables of fund usage and investment projects. It is not a brief announcement but a comprehensive verification report on fundraising activities and fund management for the year 2023. This matches the characteristics of an Audit Report / Information (AR), which covers audit results and compliance related to specific financial activities, in this case, the use of raised funds. It is not an Annual Report (10-K) or Interim Report (IR) as it focuses specifically on fundraising and fund usage verification rather than full financial performance. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial data and detailed analysis rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-18 Chinese
祥生医疗董事会审计委员会对2023年会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the performance of the appointed accounting firm (audit firm) in supervising the 2023 annual audit work. It details the audit firm's qualifications, the audit process, communication with management, and the audit committee's oversight activities. It references the 2023 annual financial report audit and internal control audit, including the issuance of an unqualified audit opinion. The document is not the full annual report itself but a standalone report on the audit firm's supervisory duties and audit quality for the year 2023. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory audits, excluding the full annual report. The document length is 2367 characters, which is short but contains substantive audit information, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-18 Chinese
无锡祥生医疗科技股份有限公司2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告摘要" (2023 Annual Report Summary) of 无锡祥生医疗科技股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and risk disclosures. The document length is over 12,000 characters, which is substantial and contains actual financial and operational data, not just an announcement or a brief summary. It also includes audit opinion information and management discussion, typical of an annual report. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2023
2024-04-18 Chinese
祥生医疗关于开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the company's plan to conduct foreign exchange hedging business. It details the business scope, necessity, risk analysis, and approvals required, including submission to the 2023 Annual General Meeting for approval. The document is a formal announcement of a corporate financing risk management activity, not a financial report or earnings release. It does not contain financial statements or detailed financial data but rather describes a planned capital/financing related activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2403 characters, which is consistent with an announcement rather than a full report.
2024-04-18 Chinese
上海市通力律师事务所关于无锡祥生医疗科技股份有限公司作废处理部分限制性股票相关事宜之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted stocks under the company's 2021 and 2022 restricted stock incentive plans. It references specific board and supervisory meetings, legal compliance with company law, securities law, stock exchange listing rules, and stock incentive plan regulations. The document is a standalone legal opinion on a specific corporate action related to stock incentive plans, not a full annual or interim financial report, earnings release, or shareholder meeting materials. It does not contain financial statements or earnings data but focuses on legal compliance and authorization of the stock cancellation. This fits the category of an Audit Report / Information (AR) as it relates to regulatory compliance and internal verification of a corporate action, rather than a full annual report or other categories. The document length (8185 characters) and detailed legal analysis support this classification with high confidence. FY 2023
2024-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.